Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984119 | 0.90 | BRD4 (0.44) | BRD4HSF1EGFRROCK1NTRK1 | |
| SCHEMBL9984339 | 0.88 | BRD4 (0.42) | BRD4HSF1EGFRABCG2 | |
| SCHEMBL9984879 | 0.87 | BRD4 (0.45) | BRD4HSF1RAB9AL3MBTL1MEN1 | |
| SCHEMBL9984994 | 0.85 | BRD4 (0.43) | BRD4HSF1RAB9AMEN1KMT2A | |
| SCHEMBL9985113 | 0.83 | EGFR (0.43) | BRD4HSF1EGFRRAB9ACYP26A1 | |
| SCHEMBL9983283 | 0.83 | GAA (0.43) | BRD4ABCG2RAB9AL3MBTL1MEN1 | |
| SCHEMBL9985029 | 0.83 | BRD4 (0.42) | BRD4HSF1ROCK1RAB9AMEN1 | |
| SCHEMBL9985176 | 0.83 | CYP17A1 (0.43) | BRD4HSF1EGFRROCK1ABCG2 | |
| SCHEMBL9984024 | 0.83 | BRD4 (0.41) | BRD4HSF1ABCG2RAB9ACYP26A1 | |
| SCHEMBL9984853 | 0.82 | HSF1 (0.54) | BRD4HSF1NTRK1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | claimed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | BRD4 1137/4885HSF1 4685/4885EGFR 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.